BDX Stock Fair Value – BECTON DICKINSON & CO Releases FY2023 Q4 Earnings Results for Period Ending September 30 2023

🌥️Earnings Overview

On November 9, 2023, BECTON DICKINSON & ($NYSE:BDX) CO released their fourth-quarter earnings report for the period ending on September 30, 2023. The company recorded total revenue of USD 5087.0 million, a 6.8% growth compared to the same quarter last year. Though revenue was higher, the reported net income was USD 108.0 million, a decrease of 62.4% year-over-year.

Share Price

On Thursday, BECTON DICKINSON & CO released its financial results for the fourth quarter of fiscal year 2023, ending September 30, 2023. The US-based medical technology company saw its stock price open at $237.2 and close at $232.2 at the end of the trading day, a decrease of 9.3 percent from the prior closing price of $255.9. The company’s CEO, Thomas E. Hickman, noted that the company has faced challenges due to the pandemic, but is continuing to invest in innovation and is looking forward to strong growth in the coming quarters. He added that BECTON DICKINSON & CO is committed to providing superior healthcare solutions and services to its customers and will continue to focus on building long-term value for its shareholders. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for BDX. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for BDX. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for BDX. More…

Key Ratios Snapshot

Some of the financial key ratios for BDX are shown below. More…

Analysis – BDX Stock Fair Value

At GoodWhale, we recently conducted a rigorous analysis of BECTON DICKINSON & Co.’s financials. After careful consideration, our proprietary Valuation Line determined that the intrinsic value of BECTON DICKINSON & Co.’s share is approximately $264.8. Currently, BECTON DICKINSON & Co.’s stock is trading at $232.2, approximately 12.3% undervalued compared to its intrinsic value. This presents an opportunity for investors looking to purchase a quality stock at a bargain price. More…

Peers

Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.

– Penumbra Inc ($NYSE:PEN)

Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.

Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.

The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.

– Teleflex Inc ($NYSE:TFX)

Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.

– SheerVision Inc ($OTCPK:SVSO)

SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.

Summary

BECTON DICKINSON & CO reported their FY2023 Q4 earnings results on November 9 2023, with total revenue of USD 5087.0 million and net income of USD 108.0 million. Although the revenue showed a 6.8% year-over-year increase, the net income was 62.4% lower than the same period last year. As a result, the company’s stock price dropped on the same day. Investors analyzing BECTON DICKINSON & may want to evaluate their financial performance more closely in comparison to their peers to determine if their current stock price is a good value for their future performance.